+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Apixaban Market: By dosage form (capsule and tablet), and end-users (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies and Others)- Global Industry Perspective Comprehensive Analysis and Forecast, 2019-2025

  • ID: 5143678
  • Report
  • November 2019
  • Region: Global
  • 130 pages
  • Zion Market Research
The report covers forecast and analysis for the Apixaban market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Apixaban market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Apixaban market on a global level. In order to give the users of this report a comprehensive view on the Apixaban market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein dosage form, end-users and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

Apixaban is a Food and Drug Administration (FDA) licensed anticoagulant used in the treatment of thromboembolic venous events (blood clot) within a vein. Venous thromboembolic events (VTEs) occurring without any prior symptoms or warning signs and may go undiagnosed or unrecognized by a health care professional. Symptoms that occur may be associated with either pulmonary embolism (PE) or deep vein thrombosis (DVT) such as calf pain, ankle and foot swelling, redness or visible spots of discolouration, rapid respiration, chest pain, or others. Apixaban is sold under Eliquis's trade name. Factor Xa is a serine protease-like trypsin that plays a important role in the cascade of blood coagulation. Apixaban mechanism works on Xa factor inhibiting which indirectly decreases thrombin-stimulated clot formation. Apixaban is recommended in patients with non-valvular atrial fibrillation to reduce the risk of stroke or systemic embolism. Eliquis' recommended dose is 5 mg twice daily orally. Apixaban is available on the market in the form of pills or tablets.

The study provides a decisive view on the Apixaban market by segmenting the market based on dosage form, end-user and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on dosage form, the market is segmented into capsule and tablet. Based on end-users, the apixaban market is segmented into hospitals, clinics, retail pharmacies, online pharmacies and others.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries such as US, Canada, Germany, UK, France, China, Japan, India, GCC countries, Brazil. In terms of revenue generated by the drug's high price, North America holds the dominant position in treating venous thromboembolic events. For example, according to a study published in the 2010 American Journal of Preventive Medicine, venous thromboembolism (VTE) affects between 300,000-600,000 people annually in the U.S., causing significant mortality. Additionally, the disorder of venous thromboembolism (VTE) may occur in all ethnicities, all age groups, and both sexes.

Increasing prevalence of conditions related to venous thromboembolism is expected to support apixaban market growth. For example, according to facts from the International Society on Thrombosis and Haemostasis 2014, around 10 million cases of venous thromboembolism occur in low, middle and high-income countries annually. In 2014, for example, the U.S. Eliquis was approved by the Food and Drug Administration for the treatment of deep vein thrombosis (DVT) prophylaxis and pulmonary embolism (PE) and also for the reduction of the risk of recurrent PE and DVT after initial treatment. In addition, government and private organizations are investing heavily in research and development in health care, and this is also likely to boost the growth of the Apixaban market. However, it is expected that adverse effects of apixaban such as increased risk of thrombotic events following premature discontinuation and bleeding will hinder its adoption. This in turn is projected to have an adverse impact on market growth.

Key players within global Apixaban market include Abbott, Alere, Bristol-Myers Squibb, C. H. Boehringer Sohn, CoaguSense, Pfizer, Portola Pharmaceuticals, Roche, Siemens amongst others.

The report segments global Apixaban market as follows:

Global Apixaban Market: Dosage Form Segment Analysis
  • Capsule
  • Tablet
Global Apixaban Market: End-user Segment Analysis
  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Global Apixaban Market: Regional Segment Analysis
  • North America
  • U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Apixaban Market, 2016-2025 (USD Million)
    • 2.2. Apixaban Market: Snapshot
  • Chapter 3. Apixaban Market - Industry Analysis
    • 3.1. Apixaban Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Dosage Form
      • 3.6.2. Market attractiveness analysis By End-user
      • 3.6.3. Market attractiveness analysis by Region
  • Chapter 4. Apixaban Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Apixaban Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Dosage Form launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Apixaban Market -Dosage Form Analysis
    • 5.1. Global Apixaban Market overview: ByDosage Form
      • 5.1.1. Global Apixaban Market share, By Dosage Form,2018 and 2025
    • 5.2. Capsule
      • 5.2.1. Global Apixaban Market by Capsule, 2016-2025 (USD Million)
    • 5.3. Tablet
      • 5.3.1. Global Apixaban Market by Tablet, 2016-2025 (USD Million)
  • Chapter 6. Global Apixaban Market -End-user Analysis
    • 6.1. Global Apixaban Market overview: By End-user
      • 6.1.1. Global Apixaban Market share, By End-user, 2018 and 2025
    • 6.2. Hospitals
      • 6.2.1. Global Apixaban Market By Hospitals, 2016-2025 (USD Million)
    • 6.3. Clinics
      • 6.3.1. Global Apixaban Market By Clinics, 2016-2025 (USD Million)
    • 6.4. Retail Pharmacies
      • 6.4.1. Global Apixaban Market By Retail Pharmacies, 2016-2025 (USD Million)
    • 6.5. Online Pharmacies
      • 6.5.1. Global Apixaban Market By Online Pharmacies, 2016-2025 (USD Million)
    • 6.6. Others
      • 6.6.1. Global Apixaban Market By Other End-users, 2016-2025 (USD Million)
  • Chapter 7. Global Apixaban Market - Regional Analysis
    • 7.1. Global Apixaban Market overview: by Region
      • 7.1.1. Global Apixaban Market share, by Region, 2018 and 2025
    • 7.2. North America
      • 7.2.1. North America Apixaban Market, 2016-2025 (USD Million)
      • 7.2.2. North America Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
      • 7.2.3. North America Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.2.4. The U.S.
        • 7.2.4.1. The U.S.Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.2.4.2. The U.S.Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.2.5.2. Rest of North America Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Apixaban Market, 2016-2025 (USD Million)
      • 7.3.2. Europe Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
      • 7.3.3. Europe Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.3.4. UK
        • 7.3.4.1. U.K.Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.3.4.2. U.K.Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.3.5.2. France Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.3.6. Germany
        • 7.3.6.1. Germany Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.3.6.2. Germany Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of EuropeApixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.3.7.2. Rest of EuropeApixaban Market revenue, By End-user, 2016-2025 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Apixaban Market, 2016-2025 (USD Million)
      • 7.4.2. Asia Pacific Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
      • 7.4.3. Asia Pacific Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.4.4. China
        • 7.4.4.1. China Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.4.4.2. China Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.4.5. Japan
        • 7.4.5.1. Japan Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.4.5.2. Japan Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.4.6. India
        • 7.4.6.1. India Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.4.6.2. India Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Apixaban Market, 2016-2025 (USD Million)
      • 7.5.2. Latin America Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
      • 7.5.3. Latin America Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.5.4.2. Brazil Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
      • 7.5.5. Rest of Latin America
        • 7.5.5.1. Rest of Latin America Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
        • 7.5.5.2. Rest of Latin America Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa Apixaban Market, 2016-2025 (USD Million)
      • 7.6.2. The Middle East and Africa Apixaban Market revenue, By Dosage Form,2016-2025 (USD Million)
      • 7.6.3. The Middle East and Africa Apixaban Market revenue, By End-user, 2016-2025 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1. Abbott
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Dosage Form Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Alere
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Dosage Form Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Bristol-Myers Squibb
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Dosage Form Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. C. H. Boehringer Sohn
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Dosage Form Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. CoaguSense
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Dosage Form Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Pfizer
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Dosage Form Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Portola Pharmaceuticals
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Dosage Form Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. Roche
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Dosage Form Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Siemens
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Dosage Form Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
Note: Product cover images may vary from those shown
Adroll
adroll